This review/meta-analysis reports that citicoline improves cognitive impairment across vascular and neurodegenerative conditions and cites evidence for benefit in mild cognitive impairment in Parkinson's disease with suggested dosing regimens (e.g., 1000 mg/day for 12–18 months).

The paper highlights a clinically tested, readily repurposable agent with pragmatic dosing data for symptomatic cognitive benefit in PD, offering translational trial potential, but it lacks PD-specific mechanistic or disease‑modifying evidence (alpha‑synuclein, mitochondrial, inflammatory, or…

Randomized controlled trials, systematic reviews, and meta-analyses have shown that citicoline is highly effective in the treatment of vascular cognitive impairments (CI) of various origins (post-stroke, chronic cerebral ischemia (CCI)), post-traumatic CI, mild CI in neurodegenerative diseases (Alzheimer's disease, Parkinson's disease), and in patients with age-related memory impairments. Citicoline administration regimens: 1) post-stroke CI at a dose of 1000 mg/day. for a course of 4-12 months; 2) mild CI of vascular origin at a dose of 500 mg/day for a course of 3-9 months; 3) CI against the background of CCI at a dose of 500-2000 mg, the duration of the course depends on the severity of the symptoms; 4) non-demented CI at a dose of 1000 mg/day course of 9 months; 5) mild CI against Parkinson's disease at a dose of 1000 mg/day 12-18 months.